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Abstract 
COVID‑19 has caused great devastation in the past year. Multi‑organ point‑of‑care ultrasound (PoCUS) including lung 
ultrasound (LUS) and focused cardiac ultrasound (FoCUS) as a clinical adjunct has played a significant role in triaging, 
diagnosis and medical management of COVID‑19 patients. The expert panel from 27 countries and 6 continents with 
considerable experience of direct application of PoCUS on COVID‑19 patients presents evidence‑based consensus 
using GRADE methodology for the quality of evidence and an expedited, modified‑Delphi process for the strength of 
expert consensus. The use of ultrasound is suggested in many clinical situations related to respiratory, cardiovascular 
and thromboembolic aspects of COVID‑19, comparing well with other imaging modalities. The limitations due to 
insufficient data are highlighted as opportunities for future research.
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Introduction
Since the first reports from China [1], SARS-CoV-2 
has caused considerable morbidity and mortality from 
COVID-19 globally [1]. Although respiratory signs and 
symptoms are the most common manifestations, other 
systems may be involved [2]. Clinical presentations 
range from mild (80%) to life-threatening (5%), usually as 
acute respiratory distress syndrome (ARDS). Paucity of 
evidence, and urgency to adjust to evolving clinical sce-
narios have prompted adoption of approaches based on 
institutional experience [3], limited evidence, or extrapo-
lation from other conditions [4, 5].
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Point-of-care ultrasound (PoCUS) is a rapid, bedside, 
goal-oriented, diagnostic test that is used to answer spe-
cific clinical questions [6]. These distinctive features are 
appealing and address concerns of environmental con-
tamination and disinfection of larger devices such as 
chest X-ray (CXR) and computed tomography (CT). 
Thus, multi-organ PoCUS could enhance the manage-
ment of COVID-19 (Fig. 1).
Methods
We searched Medline, Pubmed Central, Embase, 
Cochrane, Scopus and online pre-print databases from 
01/01/2020 to 01/08/2020, and collected all English 
language publications on PoCUS in adult COVID-19 
patients, using the MeSH query: [(“lung” AND “ultra-
sound”) OR “echocardiography” OR “Focused cardiac 
ultrasound” OR “point-of-care ultrasound” OR “venous 
ultrasound”] AND [“COVID-19” OR “SARS-CoV2”]. This 
systematic search strategy (Fig.  2) [Additional file  1A] 
identified 214 records.
The available evidence for PoCUS in COVID-19 was 
considered. Where such evidence was not available, non-
COVID-19 data were used. We then applied an expedited 
2-round modified Delphi process to elicit a consensus 
from an expert panel [Additional file 1A], who voted on 
PICO statements in 9 distinct domains (Table 1) ] [Addi-
tional file 1B] and approved the final recommendations. 
Consistent literature was GRADEd. Summary recom-
mendations were generated based on voting results, lit-
erature evidence and experts’ input presented with Level 
of Quality of Evidence (LQE: I, II-A, II-B, III) and Level of 
Agreement (Very Good, Good, Some, None) [Additional 
file 1C]  . Lastly, we identified limitations of PoCUS and 
areas of future research.
DOMAINS 1—Diagnosis of SARS‑CoV‑2 infection, 
2—Triage/disposition and 3—Diagnosis 
of COVID‑19 pneumonia
COVID-19 almost invariably involves the respiratory 
system [2]. Approximately 5% of patients require criti-
cal care and mechanical ventilation, usually due to viral 
pneumonia and/or ARDS [7]. The diagnosis of COVID-
19 pneumonia is challenging:
• Although CT has the best diagnostic yield [8], access 
is limited by patient volume, resources and risk of 
environmental contamination.
• Pre-existing conditions [9], and acute exacerbations 
of these diseases are common.
• Instability may preclude intra-hospital transporta-
tion.
• Delays or unreliability of reverse-transcriptase poly-
merase-chain-reaction (RT-PCR) results complicate 
infection control [10].
• Several algorithms/approaches developed for triage 
[11–20] are perceived as helpful, but remain unvali-
dated.
Evidence
LUS is more accurate than CXR for diagnosing respira-
tory conditions [21], including interstitial diseases [22], 
pneumonia [23] and COVID-19 pneumonia [24]. The 
diagnostic accuracy of addition of LUS outperforms 
standard emergency department tests for dyspnea [25, 
26]. LUS can diagnose COVID-19 pneumonia in patients 
with normal vital signs [27] and distinguish viral and bac-
terial pneumonias [28].
LUS findings associated with COVID-19 pneumonia 
are reported to be similar to previously described viral 
pneumonias [12, 22]. Frequently observed are [Additional 
files 2–5]: heterogeneous B-lines clusters, separated or 
confluent (corresponding to ground glass opacities on 
CT), large band-like longitudinal artifacts arising from 
normal pleural line (characterized as “light beam” [12]), 
pleural line irregularities, subpleural consolidations and 
areas with decreased lung sliding due to poor ventilation. 
Large consolidations with air bronchograms may be pre-
sent, more commonly in patients requiring mechanical 
ventilation, possibly representing progression to ARDS 
or superimposed bacterial infection. At presentation, the 
distribution, although bilateral, is usually asymmetrical 
and patchy [29–31]. Lung involvement may be limited 
to dorsal/basal areas in milder COVID-19 pneumonia 
[32]. LUS shows good agreement with CT in recogniz-
ing lung pathology and its severity [33, 34] thus, identify-
ing patients at higher risk of clinical deterioration, ICU 
admission, mechanical ventilation and mortality [34–36]. 
B-line count, consolidations and thickened pleural lines 
are associated with positive RT-PCR tests and clinical 
severity [37, 38]. Coupled with pretest probability, bilat-
eral B-lines [single and/or confluent], irregular pleural 
line and subpleural consolidations increase the likeli-
hood of diagnosing COVID-19 [39, 40], while non-spe-
cific, bilateral heterogeneous patterns [Additional file 6], 
combined with a typical clinical presentation, strongly 
suggest viral pneumonia. Conversely, if pre-test probabil-
ity is low [41], a bilateral A-pattern on LUS may exclude 
COVID-19 pneumonia owing to its high negative predic-
tive value for pneumonia [12, 30].
Multi-organ PoCUS yields a better diagnostic per-
formance for causes of respiratory failure than LUS 
alone [42]. As a rapid, accurate diagnostic approach to 
acute dyspnea [43–45], it outperforms standard tests 
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Fig. 1 Graphical synopsis of potentially useful applications of point‑of‑care ultrasound (PoCUS) in COVID‑19 patients. ABD, abdominal ultrasound; 
ACP, acute cor pulmonale; AKI, acute kidney injury; DUS, diaphragmatic ultrasound; DVT, ultrasound for deep venous thrombosis screening; ECHO, 
echocardiography; FoCUS, focused cardiac ultrasound; LUS, lung ultrasound; MUS, parasternal intercostal muscles ultrasound; ONSD, optic nerve 
sheath diameter; PEEP, positive end expiratory pressure; PoCUS, point‑of‑care ultrasound; TCD, transcranial Doppler; VASC, ultrasound for venous 
and arterial access
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[26]. Similar results have been reported in undifferenti-
ated shock [46]. PoCUS is recommended as a first-line 
diagnostic test for investigating respiratory failure and/
or hypotension [22, 47]. PoCUS may raise suspicions of 
falsely negative RT-PCR and/or alternate diagnoses [48]. 
Recognition of comorbidities (chronic RV or LV dysfunc-
tion) and COVID-19-associated complications (DVT and 
RV failure) may influence patient disposition, and PoCUS 
can change their management [40].
We present a conceptual framework for triage of res-
piratory failure [Additional file  7]. Without more data, 
triage protocols cannot be developed that are universally 
applicable.
Recommendations
1 We suggest using PoCUS, and especially LUS (pres-
ence of heterogeneous B-line clusters, pleural line 
irregularities, subpleural consolidations), and appro-
priately integrate the information with clinical assess-
ment to diagnose COVID-19 pneumonia (LQE II-B, 
Very Good Agreement).
Fig. 2 Literature search strategy. A literature search of Pubmed, Pubmed Central, Embase, Scopus and Cochrane library databases was conducted 
by 2 independent researchers from 01/01/2020–01/08/2020 to identify all publications on point‑of‑care ultrasound in COVID‑19 adult patients, 
using English language restriction, and the following MeSH query: ((“lung” AND “ultrasound”) OR “echocardiography” OR “Focused cardiac 
ultrasound” OR “point‑of‑care ultrasound” OR “venous ultrasound”) AND (“COVID‑19” OR “SARS‑CoV2”). Non‑pertinent findings were discarded. The 
references of relevant papers were hand‑searched for missed papers. Duplicates were removed. An additional search of pre‑print publications was 
made through ResearchGate, preprint online repositories and social medias
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2 When CT-scan is not accessible or appropriate, we 
suggest using LUS to aid the diagnosis of COVID-
19 pneumonia in suspected cases (LQE II-B, Good 
Agreement).
3 In patients with high pre-test probability for COVID-
19 and LUS findings suggestive of pneumonia, a neg-
ative nasal/oropharyngeal RT-CR may not be used to 
exclude COVID-19, and LUS findings, further raising 
suspicion, should prompt repeat testing with better 
yield (LQE II-B, Good Agreement).
4 We do not recommend using PoCUS and LUS alone 
to rule out SARS-CoV-2 infection in suspected 
COVID-19 (LQE II-B, Good Agreement).
5 After thorough examination of all lung fields and 
intercostal spaces, a bilateral A-pattern suggests 
absence of pneumonia in suspected or confirmed 
SARS-CoV-2 infection (LQE III, Good Agreement).
6 We suggest multi-organ PoCUS integrated with other 
clinical information for triaging and risk stratification 
of suspected COVID-19 at initial presentation (LQE 
II-B, Good Agreement).
Limitations and future research
More data are required to establish the accuracy of LUS 
findings for the diagnosis of COVID-19 pneumonia ver-
sus other viral pneumonias. PoCUS use for risk stratifica-
tion, outcome prediction, and its impact on management 
of COVID-19 needs study.
DOMAIN 4—Cardiovascular diagnosis in COVID‑19
Numerous cardiovascular issues are associated with 
COVID-19:
• Patients with cardiovascular comorbidities seem to 
develop more severe COVID-19 [49].
• Up to 17% of hospitalized COVID-19 patients sus-
tain acute cardiac injury (ACI) that increases mor-
tality [50, 51–53]. Besides the inflammatory and 
direct cellular injury, other possible mechanisms 
for ACI include hypoxemia and result in oxygen 
supply/demand imbalance [54]. A close association 
of acute and fulminant myocarditis with COVID-19 
is not established. However, if present, it will result 
in low output syndrome or cardio-circulatory col-
lapse [55]. Though high-sensitivity troponin assays 
allow detection of myocardial injury, no cutoff val-
ues reliably distinguish myocardial infarction (MI) 
from other ACI [56]. Elevation of cardiac biomark-
ers, ECG changes, LV and RV dysfunction [57, 58] 
have been reported in myocarditis and AMI [55, 
59].
• It is difficult to distinguish the effects of pneumonia 
from superimposed congestive heart failure [59].
• Respiratory acidosis, alveolar inflammatory edema 
and microvascular alterations may increase pulmo-
nary vascular resistance [60], and positive pressure 
ventilation may further increase RV afterload, pre-
cipitating RV failure [61].
• Various cardiac manifestations [62] have been 
described, and some critically ill COVID-19 patients 
exhibit shock states [51].
Evidence
Echocardiography and FoCUS are established tools for 
diagnosing cardiovascular disease [47, 63, 64]. FoCUS 
can detect pre-existing cardiac disease [Additional file 8] 
and acute RV and/or LV dysfunction [47]. Echocardiog-
raphy [65] and FoCUS are recommended by American 
and European Echocardiography societies as diagnostic/
monitoring tools in COVID-19 [66, 67]. FoCUS can guide 
decisions on coronary angiography [68] and inotropic/
mechanical circulatory support [59, 69, 70]. Overt symp-
toms of myocardial ischemia, raised cardiac biomarkers, 
ECG changes and new LV regional wall motion abnor-
malities should be carefully evaluated so that myocardial 
infarction [Additional file 9] diagnostic/therapeutic path-
ways are followed expediently [54, 67, 68]. Low voltage 
QRS complexes, myocardial hyper-echogenicity, diffuse 
hypokinesia or regional wall motion abnormalities sug-
gest myocarditis [71] [Additional file 11]. Acute cor-pul-
monale can occur in COVID-19 [58, 72], and FoCUS can 
detect RV dilatation, paradoxical septal motion and RV 
longitudinal dysfunction [47] [Additional file  10]. Thus, 
FoCUS/echocardiography together with clinical and bio-
chemical indices can enhance management of cardiovas-
cular compromise.
Table 1 PoCUS domains considered for  consensus 
recommendations
Domain 1 PoCUS for Sars‑Cov‑2 infection diagnosis
Domain 2 PoCUS as a tool for triage/disposition
Domain 3 PoCUS for diagnosis of COVID‑19 pneumonia
Domain 4 PoCUS for cardiovascular diagnosis
Domain 5 PoCUS for screening and diagnosis of thromboembolic 
disease
Domain 6 PoCUS and respiratory support strategies
Domain 7 PoCUS for management of fluid administration
Domain 8 PoCUS for monitoring of COVID‑19 patients
Domain 9 PoCUS and infection control, techniques, technology and 
protocols
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Recommendations
7. We suggest FoCUS and/or echocardiography assess-
ment in moderate-severe COVID-19 as it may 
change clinical management or provide information 
that could be lifesaving (LQE II-B, Very Good Agree-
ment).
8 We suggest FoCUS and/or echocardiography for 
assessment of hemodynamic instability in moder-
ate-severe COVID-19 (LQE II-B, Very Good Agree-
ment).
9 We recommend FoCUS and echocardiography to 
diagnose RV and LV systolic dysfunction and cardiac 
tamponade as etiology of hemodynamic instability in 
COVID-19 (LQE II-B, Very Good Agreement).
10 We suggest using FoCUS/echocardiography to guide 
hemodynamic management in severe COVID-19 
(LQE II-B, Very Good Agreement).
Limitations and future research
Whether subtypes of COVID-19 exist with more severe 
cardiovascular involvement and worse prognosis, 
requires investigation. Study of diastolic function may 
be of interest in COVID-19.
DOMAIN 5—Screening and diagnosis of venous 
thromboembolic disease (VTE)
The risk of VTE in COVID-19 is high:
• Due to high incidence of DVT [73, 74] [Additional 
file 13].
• Pulmonary embolism (PE) [75, 76] [Additional 
file  10] and clotting in renal replacement circuits 
[75] in COVID-19 ICU patients are early and late 
complications.
• COVID-19 is associated with immunothrom-
botic dysregulation [77]. This manifests with high 
D-dimer [78], high C-reactive protein levels, anti-
phospholipid antibodies [75] and sepsis-induced 
coagulopathy [79], and is likely to increase mortal-
ity [79].
• Screening for coagulopathy can risk stratify 
patients and may determine the need for antico-
agulation [80]. However, higher D-dimer cutoffs 
may be needed to improve its specificity for DVT 
in COVID-19 [81].
• Whether DVT detection at hospital admission sug-
gests more severe COVID-19 remains unknown.
• Despite standard thromboprophylaxis DVT is com-
mon in COVID-19 [81, 82].
Evidence
Ultrasound is the mainstay of DVT diagnosis [83]. 
Screening is advised, when feasible, in the general 
management of COVID-19 patients [84]. Many fac-
tors limit access to formal duplex venous sonography 
[85]. Although routine screening is not widely recom-
mended [86], twice weekly ultrasound surveillance 
can detect DVT, avert PE and reduce mortality in ICU 
patients [87].
Lower extremity ultrasound is recommended in 
COVID-19 patients with unexplained RV dysfunction, 
unexplained/refractory hypoxemia, or in patients with 
suspected PE who are too unstable for intra-hospital 
transport [86].
Recommendations
11. Because critically ill COVID-19 patients have high 
risk for VTE, we suggest regular screening for DVT, 
including central vessels with catheters, independ-
ent of oxygenation and coagulation (LQE II-A, Very 
Good Agreement).
12 In moderate-severe COVID-19 with hemodynamic 
worsening or sudden instability, we suggest FoCUS 
for prompt investigation of acute cor-pulmonale 
(LQE II-B, Very Good Agreement).
13 In moderate-severe COVID-19, we suggest that 
echocardiographic indices of worsening RV function 
and/or increased pulmonary artery pressure may 
indicate PE (LQE II-A, Very Good Agreement).
Limitations and future research
DVT prevalence and its role in risk stratification in 
mild COVID-19 are not known. Correlation of DVT 
with different COVID-pneumonia phenotypes needs 
study.
DOMAIN 6—PoCUS and respiratory support 
strategies [including mechanical ventilation]
Phenotypes of COVID-19 pneumonia associated 
with similar degrees of hypoxemia but different lung 
weight,  aerated  volume and compliance have been 
described [88]. These range from “classic” ARDS (Phe-
notype-H) that responds to higher PEEP, to the better 
aerated low elastance (Phenotype-L) that often requires 
lower PEEP [89]. Future studies may clarify whether 
phenotyping COVID-19 pneumonia can guide respira-
tory support, mechanical ventilation settings, and min-
imize ventilator-induced lung injury [89].
“Classic” ARDS commonly involves dependent lung 
regions [90]; the same areas are typically involved in 
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advanced COVID-19 pneumonia [89, 91]. Localizing 
consolidated lung is important to maximize benefit 
from prone positioning. Prone positioning is preferable 
when dorsal consolidation is severe with spared ventral 
zones [92]. Prone positioning in non-intubated patients 
may rapidly improve oxygenation [93, 94].
Evidence
Like CT, LUS accurately characterizes regional lung 
pathology and identifies ARDS in COVID-19 pneumo-
nia [33, 34, 40, 95]. LUS may discriminate mild-moderate 
from moderate-severe aeration loss, distinguishing dif-
ferent ARDS phenotypes [96] (Fig. 3).
Importantly, LUS may facilitate identification of 
patients with greater hypoxemia than expected for their 
alveolar lung injury (Fig. 3), in whom the pathophysiology 
may involve deranged perfusion (PE, micro-thrombosis, 
loss of pulmonary vasoconstriction, extrapulmonary 
shunt).
Global LUS score is strongly associated with lung tis-
sue density/aeration measured with CT [97]. Using LUS 
to guide mechanical ventilation has been recommended 
[98] (Fig. 4). However, recruitment demonstrated by LUS 
correlates with recruitment estimated by pressure–vol-
ume curves [99], but not CT [97]. Although LUS may 
not predict oxygenation response to prone positioning, 
it does predict re-aeration of dorsal zones [100] (Fig. 5). 
LUS findings also correlate with extravascular lung water 
in ARDS [101, 102] and can monitor changes in aera-
tion [103]. This has also been suggested in COVID-19 
[104–106].
Recommendations
14. We suggest multi-organ PoCUS including LUS over 
no imaging to guide respiratory support in COVID-
19 with respiratory failure (i.e. ventilation, prone 
positioning, PEEP, recruitment maneuvers) (LQE 
II-A, Good Agreement).
15 In addition to standard respiratory monitoring, we 
suggest LUS over CXR and equally to CT, to guide 
clinical decisions on respiratory support in COVID-
19 with respiratory failure (LQE II-B, Good Agree-
ment).
16 We suggest multi-organ PoCUS over LUS alone for 
decisions about respiratory support in COVID-19 
with respiratory failure (LQE II-B, Good Agreement).
Limitations and future research
The benefit of LUS in ventilated COVID-19 patients is 
only theoretical. Studies to predict response to prone 
positioning, PEEP titration and other interventions are 
awaited. Role of LUS to decide invasive mechanical venti-
lation is unknown.
DOMAIN 7—Management of fluid administration 
in COVID‑19 patients
Fluid management is fundamentally important and often 
challenging in critically ill patients [107]. In COVID-19 
patients, fluid overload can exacerbate lung dysfunction. 
Recent recommendations stress the need for conserva-
tive fluid strategies [4].
Evidence
A large international survey found that PoCUS was the 
most frequently used approach to assess fluid respon-
siveness in critically ill COVID-19 patients [108]. While 
FoCUS can detect early signs of severe central hypov-
olemia [47] [Additional file 12], interpretation of inferior 
and superior vena cava collapsibility/distensibility indices 
is difficult when a variety of ventilation modalities are 
employed [18, 109]. Transesophageal echocardiography 
has inherent risks and limitations related to manpower 
and infection control [110].
Dynamic indices based on stroke volume variation, pas-
sive leg raising and mini-bolus administration techniques 
are good predictors of fluid responsiveness [111, 112] and 
can be assessed with transthoracic echocardiography.
In non-COVID-19 pneumonia patients, LUS has been 
shown to provide information on fluid tolerance and 
detect the consequences on the lung of overzealous fluid 
(See figure on next page.)
Fig. 3 Examples of lung ultrasound cumulative patterns of patients presenting with a similar degree of hypoxemia, but very different degree of 
aeration and respiratory mechanics characteristics, and recalling the recently proposed COVID‑19 pneumonia phenotypes [89]. Patient on upper 
panel presents a nearly normal respiratory system compliance and LUS evidence of a milder lung involvement, reflected in a total LUS score of 11. 
This suggests a lung condition matching which has been recently described as “Phenotype L,” based on CT findings, and characterized by low lung 
elastance and low ventilation/perfusion ratio (explaining the severe hypoxia). Based on this imaging and on respiratory mechanics findings, final 
PEEP was set at 10 cm H20. Upper panel shows LUS evidence of a more diffuse and severe diffuse sonographic interstitial syndrome (cause of the 
shunt and the severe hypoxia), yielding a total LUS score of 27. Respiratory mechanics characteristics recall what has been described as “Phenotype 
H” (COVID‑19 pneumonia: high lung elastance, high right‑to‑left shunt). Based on this imaging and on respiratory mechanics findings, PEEP was set 
at 14 cm H20 after a stepwise recruiting maneuver. LUS, lung ultrasound
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resuscitation [113, 114]. Resolution of B-lines during 
hemodialysis has been described [115] and also observed 
in COVID-19 patients [116, 117].
Recommendations
17. We suggest FoCUS to screen for severe hypovolemia 
in moderate-severe COVID-19 at presentation, while 
Doppler-based fluid-responsiveness indices may be 
used for subsequent management (LQE II-A, Very 
Good Agreement).
18 We suggest that LUS alone is not sufficient as a 
screening tool for pulmonary congestion in moder-
ate-severe COVID-19 (LQE III, Very Good Agree-
ment).
19 We suggest that LUS alone is not sufficient to judge 
the appropriateness of fluid administration in moder-
ate-severe COVID-19 (LQE II-B, Very Good Agree-
ment).
20 In moderate-severe COVID-19, we suggest multi-
organ PoCUS to monitor efficacy of fluid removal, 
by not only LUS findings of reduction of B-pattern 
areas, but also echocardiographic signs of resolution 
of volume overload and decreasing LV filling pres-
sures (LQE II-B, Very Good Agreement).
Limitations and future research
In COVID-19 pneumonia, the severity of the bilateral 
interstitial manifestations may either be due to variations 
in the inflammatory condition of the lung or changes due 
to pulmonary congestion. Simplified PoCUS-guided fluid 
management could be beneficial in resource-limited set-
tings and needs further studies.
DOMAIN 8—Monitoring patients with COVID‑19
PoCUS FOR RESPIRATORY MONITORING: 
COVID-19 pneumonia is characterized by a wide spec-
trum of clinical presentations, from mild-moderate 
hypoxia to severe manifestations requiring life-sustaining 
measures [118]. In  situations where large numbers of 
patients are admitted to areas with limited monitoring 
and staffing, disease progression may go unrecognized. 
Moreover, rapid progression to respiratory arrest has 
been reported [119]. Severe COVID-19 pneumonia is 
characterized by severe respiratory failure [120], but not 
necessarily as ARDS.
Evidence
Evolution of LUS findings and their quantification using 
scoring systems are effective in monitoring progression 
Fig. 4 Use of lung ultrasound to monitor lung aeration and guide ventilatory management in 2 COVID‑19 patients. a COVID‑19 patient on day 
2 after intubation and ICU admission, initially with PEEP 12  cmH2O: diffuse bilateral B‑pattern with crowded, coalescent B‑lines (“white lung 
appearance”) is visible, consistent with a sonographic interstitial syndrome and severe loss of aeration/increase of extravascular lung water. 
Based on these findings and on respiratory mechanics, a stepwise recruitment maneuver with a final PEEP set at 15  cmH20 was performed, with 
improvement in gas exchange. b A different COVID‑19 patient on day 4; PEEP set at 14  cmH2O: in comparison with previous patient, less B‑lines 
are visible in ventral scans, with asymmetric distribution (more on the left scan); dorsal areas show lung consolidations, larger on the right side, 
with air bronchograms (dynamic at live scan). A pronation trial was successful, yielding immediate improvement in gas exchange and subsequent 
re‑aeration of dorsal areas. (Ventral scans are taken with a linear, high frequency probe, dorsal ones with a phased array low‑frequency one)
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or resolution of lung injury, especially in terms of vari-
ations in aeration and extravascular water content [22, 
98, 103, 121, 122]. LUS is very sensitive, but is not spe-
cific enough to identify all causes of respiratory dete-
rioration [22]. A comprehensive semi-quantitative LUS 
approach [97] can assess severity of lung injury and dis-
tribution patterns.
In patients with COVID-19 pneumonia, progression of 
LUS findings has been correlated with clinical and radi-
ological deterioration. Thus, it can accurately monitor 
the evolution throughout its spectrum of severity, from 
mechanically ventilated [104, 105, 123] or veno-venous-
ECMO patients [106], to milder cases [124,125, 126]. 
LUS has helped in identifying superimposed bacterial 
infections [127], and the response to antibiotic treatment 
[128]. LUS Monitoring has reduced use of CT and CXR 
in critically ill and COVID-19 populations [129, 130].
Recommendations
21. We suggest serial LUS for respiratory monitoring in 
moderate-severe COVID-19 (LQE II-B, Very Good 
Agreement).
22 We suggest multi-organ PoCUS integrated with other 
clinical and biochemical variables, in preference to 
CXR for investigation of respiratory deterioration in 
moderate-severe COVID-19 (LQE II-A, Very Good 
Agreement).
23 We suggest multi-organ PoCUS over LUS alone to 
detect respiratory deterioration and guide treat-
ment in moderate-severe COVID-19 (LQE II-B, Very 
Good Agreement).
Limitations and future research
LUS has limitations and requires further research in early 
identification of patients who are more likely to progress 
to severe respiratory failure with inflammation, their 
pneumonia phenotype, and separate them from those 
with congestion.
DETECTION OF MECHANICAL VENTILATION-
RELATED COMPLICATIONS: Approximately 2.5% of 
all COVID-19 patients [118] and up 88% of those admit-
ted to ICU [9] require invasive mechanical ventilation, 
which may often last for weeks. The diagnosis of com-
plications associated with prolonged ventilation requires 
imaging that may be limited due to risk of exposure to 
healthcare workers and environmental contamination. 
Thus, PoCUS, performed at the beside by the treating 
physician, may provide an accurate alternative.
Evidence
Pneumothorax. LUS has significantly higher sensitivity 
than CXR for the diagnosis of pneumothorax [79% ver-
sus 40%], whereas specificity is equally excellent [131]. 
However, most of these data are from trauma and post-
procedural studies and may overestimate diagnostic per-
formance of LUS in COVID-19. The negative predictive 
value of LUS for pneumothorax is approximately 100% 
(if pleural sliding, lung pulse and B or C patterns are 
observed) [132].
Ventilator-associated pneumonia. In the appropriate 
context, large consolidations not responsive to recruit-
ment maneuvers or suction [133] are highly suggestive of 
secondary bacterial infection [127, 134].
Diaphragmatic dysfunction, and weaning failure from 
mechanical ventilation. Ventilation-induced diaphrag-
matic injury can be reliably assessed with ultrasound 
[135]. Combining LUS score with the evaluation of LV 
and diaphragm function may improve the success of 
weaning trials [136–139]. Assessment of parasternal 
intercostal muscles thickening fraction seems promising 
for predicting weaning failure [140]. Detection and treat-
ment of unresolved pulmonary conditions can facilitate 
weaning [141, 142].
Fig. 5 Lung ultrasound to monitor adequacy of re‑aeration of dorsal 
areas upon pronation and recruitment maneuvers in a COVID‑19 
patient. Same patient of Fig. 2B, before (upper panels) and after 
(lower panels) pronation and a series of stepwise recruitment 
maneuvers up to PEEP 26  cmH2O, and final PEEP setting at 16  cmH20
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Acute cor-pulmonale. The effects of mechanical venti-
lation on RV function have been well-described. Acute 
cor-pulmonale becomes an important factor to be con-
sidered in the ventilation strategy [61, 143].
Recommendations
24. We suggest a prompt assessment of clinical deterio-
ration with LUS for a timely and accurate bedside 
diagnosis of pneumothorax in severe COVID-19 
(LQE II-B, Very Good Agreement).
25 We suggest LUS for early identification of ventilator-
associated pneumonia in severe COVID-19 (LQE 
II-B, Very Good Agreement).
26 We suggest multi-organ PoCUS over CXR and CT 
to assess readiness for weaning, predict success and 
diagnose the cause(s) of weaning failure in COVID-
19 (LQE II-B, Very Good Agreement).
Limitations and future research
The safety and cost-saving impact of LUS in diagnosing 
complications of mechanical ventilation is yet to be dem-
onstrated. A decision process based on PoCUS for tra-
cheal extubation vs. tracheostomy mandates validation.
PoCUS FOR HEMODYNAMIC MONITORING
Evidence
FoCUS and echocardiography are recommended for 
hemodynamic monitoring in critical care [47, 63, 64]. 
A recent survey found that ultrasound is the most fre-
quently used monitoring tool to assess cardiac output 
and pulmonary artery pressures in critical COVID-19 
patients [108].
Recommendations
27. We suggest FoCUS and/or echocardiography for 
hemodynamic monitoring in moderate-severe 
COVID-19 (LQE II-A, Very Good Agreement).
28 We suggest integrating PoCUS-derived information 
with data from other devices used for hemodynamic 
monitoring in severe COVID-19 (LQE II-B, Very 
Good Agreement).
Limitations and future research
Validated PoCUS-driven hemodynamic management 
protocols in COVID-19 are needed.
PoCUS FOR MONITORING OF OTHER ORGANS: 
Many critically ill COVID-19 patients develop secondary 
organ dysfunction, including acute kidney injury (AKI), 
liver injury, rhabdomyolysis and gastrointestinal com-
plications [118, 144]. Hemodynamic factors and viral 
tropism for tubular cells may contribute to AKI [145]. 
Gastrointestinal complications may result from sepsis, 
deranged hemodynamics, or microvascular thrombosis 
[75]. Neurological complications are also not infrequent 
in COVID-19 [146].
Evidence
PoCUS can exclude post- and pre-renal causes of AKI 
(by assessing volume status and hemodynamics). It can 
detect systemic and renal venous congestion, important 
factors in AKI [147, 148], acute gastrointestinal complica-
tions [149, 150] including cholestasis and bowel ischemia 
in COVID-19 patients [151]. The use of PoCUS for the 
diagnosis and management of neurological conditions is 
acknowledged [152] and may be applicable in COVID-19.
Recommendations
 29. We suggest PoCUS assessment for pre-renal causes 
of AKI, including hemodynamics and venous 
congestion in COVID-19 (LQE II-B, Very Good 
Agreement).
Limitations and future research
Expertise and data on PoCUS applications to detect 
organ dysfunction in COVID-19 especially AKI and 
acute abdomen are limited and need further study.
DOMAIN 9—Infection control, PoCUS technique, 
technology, and protocols
In the context of COVID-19:
• Interest in PoCUS has increased.
• Choice of machines is limited.
• Infection transmission to operators and environmen-
tal viral dissemination are serious concerns that may 
impact the quality of ultrasound examination and the 
choice of equipment.
• A systematic scanning approach is required to avoid 
missing or misinterpreting important findings.
Evidence
Laptop/tablet/pocket-sized machines provide reason-
able compromise between portability and capability [153] 
(Fig.  6). Multi-frequency probes may be preferable to 
visualize both deep and superficial structures. While a 
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single phased-array probe is suitable for FoCUS and LUS 
[154], a convex probe has been recommended by some 
experts [22]. Topographic zones and scanning techniques 
require standardization [12, 22, 30]. There is also a grow-
ing interest in telemedicine technology including robotic 
examinations [155] for remote guidance of minimally 
trained operators [156, 157] [Additional file 14].
To protect healthcare workers and patients, stringent 
infection control practices are crucial. Available guid-
ance deals with environmental transmission and spread 
to personnel [158]. Recommendations on disinfect-
ants [159] and information on SARS-CoV-2 survival on 
fomites [160] are also available.
Recommendations
 30. We suggest using laptop/tablet/pocket-sized 
devices with adequate imaging capabilities that 
are easier to protect from viral contamination in 
COVID-19 (LQE IIB, Good Agreement).
 31. For diagnostic accuracy, quality control and obtain-
ing second opinions, we suggest performance of 
standardized PoCUS examinations in COVID-19 
(LQE II-B, Good Agreement).
 32. We recommend reporting PoCUS studies and 
recording, storage and archiving of diagnostic 
images and cine-clips (LQE II-B, Good Agree-
ment).
 33. We suggest using tele-ultrasound for remote guid-
ance and consultations in COVID-19. Simple 
audio-visual communication devices (e.g. smart-
phones) can facilitate this (LQE II-B, Good Agree-
ment).
 34. We suggest PoCUS over CXR and CT, where 
appropriate, to reduce environmental spread of 
infection and risk of infection to healthcare work-
ers in COVID-19 (LQE IIA, Good Agreement).
 35. We recommend strict adherence to manufacturers’ 
guidance for cleaning and disinfection of equip-
ment used for COVID-19 (LQE II-A, Good Agree-
ment).
 36. We suggest brief and targeted ultrasound exami-
nations to minimize cross-infection in COVID-19 
(LQE II-B, Good Agreement).
Limitations and future research
Information on quality, safety, remote mentoring/moni-
toring and archiving in COVID-19 is limited. Evidence 
for safety and efficacy of different disinfectants and meth-
ods of cleaning contaminated equipment is needed to 
make robust infection control policies.
Conclusion
This consensus document based on the available evi-
dence and expert opinion should encourage the use of 
PoCUS to improve patient outcomes during the current 
pandemic and development of meaningful protocols and 
practices to overcome COVID-19 and prepare for future 
challenges.
Supplementary information
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Additonal file 1A. Panel Composition, Literature search
Additional file 1B. Consensus Methodology
Additional file 1C. Consensus Results and Summary Recommendations
Additional file 2. (Video 1) Lung ultrasound (LUS) findings in COVID‑19 
Pneumonia. Clusters of B‑lines. These usually have a patchy distribution
Additional file 3. (Video 2) Lung ultrasound (LUS) findings in COVID‑19 
Pneumonia. Longitudinal bright, band‑like, large artifacts
Additional file 4. (Video 3) Lung ultrasound findings (LUS) in COVID‑19 
Pneumonia. Subpleural consolidations and spared areas
Additional file 5. (Video 4) Lung ultrasound (LUS) findings in COVID‑19 
Pneumonia. Lung consolidations in dorsal areas
Additional file 6. (Video 5). Cumulative lung ultrasound pattern in a 
patient with COVID‑19 pneumonia. The exam was performed considering 
Fig. 6 Example of highly portable ultrasound device covered for 
use on COVID‑19 patients. The iPAD, with which the device works, 
is tightly enveloped in plastic film wrap, while the probe is covered 
with a dedicated sheath (normally used for sterile ultrasound‑guided 
procedures). Donning and doffing the device requires assistance 
and involves stepwise uncovering, with multiple steps of disinfection 
before and after removing the covering. Use of the device is restricted 
to the COVID‑19 unit
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3 regions per hemithorax (anterior, lateral and a posterior, with the ster‑
num, the anterior axillary line and the posterior axillary line as landmarks) 
and an upper and a lower quadrant for each one of them. The resulting 6 
areas per hemithorax are labelled with numbers from 1 to 6, and with L for 
left side and R for the right side
Additional file 7. PoCUS‑empowered triage in respiratory failure during 
COVID‑19 Pandemic. Conceptual framework of point‑of‑care ultrasound 
(PoCUS) use for the triage of dyspneic and/or hypoxemic patients, during 
the SARS‑CoV‑2 pandemic: the diagram does not represent an algorithm 
but rather a framework for potentially developing protocols according to 
local/institutional clinical practices, policies and regulations. It does not 
either provide a list of conclusive diagnosis or specific treatments, but 
suggests how to integrate at best PoCUS in the workflow of this specific 
setting
Additional file 8. (Video 6). Focused cardiac ultrasound (FoCUS) findings 
in a patient with COVID‑19 Pneumonia and pre‑existing cardiac disease. 
First panel shows a videoclip with findings consistent with chronic right 
ventricular dysfunction. Second panel shows videoclips with evidence of 
chronic left ventricular failure
Additional file 9. (Video 7). Focused cardiac ultrasound (FoCUS) findings 
in a patient with COVID‑19 pneumonia and acute myocardial infarction.
Additional file 10. (Video 8). Focused Cardiac Ultrasound (FoCUS) find‑
ings in a patient with COVID‑19 Pneumonia and acute cor pulmonale, due 
to both mechanical ventilation and submassive pulmonary embolism.
Additional file 11. (Video 9). Focused cardiac ultrasound (FoCUS) findings 
in a patient with COVID‑19 pneumonia and myocarditis.
Additional file 12. (Video 10) Focused cardiac ultrasound (FoCUS) find‑
ings in a patient with COVID‑19 pneumonia and severe hypovolemia.
Additional file 13. (Video 11). Focused cardiac ultrasound (FoCUS) 
findings in a patient with COVID‑19 pneumonia and diffuse deep venous 
thrombosis. (Courtesy of Dr. Scopigni Francesca)
Additional file 14. (Video 12). Remote guidance with tele‑ultrasound in 
the COVID‑ICU. Operators within the isolation room perform lung and 
cardiac ultrasound exam in a COVID‑19 pneumonia patient, with guid‑
ance and second opinion from a colleague in the non‑COVID zone of the 
hospital. Guidance is provided verbally and with remote control of the 
ultrasound settings. (Courtesy of Dr. Bruno Capelli)
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